Vise Technologies, Inc. Abb Vie Inc. Transaction History

Vise Technologies, Inc.

$771 Million
Q3 2024

A detailed history of Vise Technologies, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Vise Technologies, Inc. holds 20,445 shares of ABBV stock, worth $3.68 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares

20,445

Previous 17,322 18.03%

Holding current value

$3.68 Million

Previous $2.97 Million 35.88%

% of portfolio

0.52%

Previous 0.53%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$163.84 - $199.33 $511,672 - $622,507	3,123 Added 18.03%	20,445 $4.04 Million
Q2 2024 Aug 01, 2024	BUY	$154.79 - $180.76 $254,010 - $296,627	1,641 Added 10.46%	17,322 $2.97 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $54,978 - $62,642	-344 Reduced 2.15%	15,681 $2.86 Million
Q4 2023 Feb 07, 2024	SELL	$137.6 - $154.97 $174,614 - $196,656	-1,269 Reduced 7.34%	16,025 $2.48 Million
Q3 2023 Oct 31, 2023	BUY	$133.59 - $154.65 $413,995 - $479,260	3,099 Added 21.83%	17,294 $2.58 Million
Q2 2023 Aug 08, 2023	SELL	$132.51 - $164.9 $130,522 - $162,426	-985 Reduced 6.49%	14,195 $1.91 Million
Q1 2023 May 10, 2023	BUY	$144.61 - $166.54 $556,170 - $640,512	3,846 Added 33.93%	15,180 $2.42 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $3,596 - $4,312	-26 Reduced 0.23%	11,334 $1.83 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $767,412 - $880,171	5,718 Added 101.35%	11,360 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $387,950 - $493,212	2,819 Added 99.86%	5,642 $864,000
Q1 2022 Jun 08, 2022	BUY	$131.98 - $163.75 $372,579 - $462,266	2,823 New	2,823 $458,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vise Technologies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vise Technologies, Inc. with notifications on news.

Account

Vise Technologies, Inc. Abb Vie Inc. Transaction History